CBP/p300 Degrader: A Promising Therapeutic Strategy for Treatment of Prostate Cancer and Beyond.

Jiankang HuYong Xu

Published in: Journal of medicinal chemistry (2024)

Transcriptional coactivators CBP/p300 have emerged as potential targets for cancer therapeutics. This Viewpoint discusses recent results that demonstrate an exceptionally potent and orally efficacious CBP/p300 degrader for the treatment of prostate cancer. This degrader stands out as a promising new candidate for cancer therapy and deserves further research.

Keyphrases

prostate cancer
cancer therapy
radical prostatectomy
gene expression
drug delivery
squamous cell carcinoma
risk assessment
papillary thyroid
combination therapy
anti inflammatory
squamous cell
replacement therapy
climate change
human health
lymph node metastasis
smoking cessation